Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate

INTRODUCTION: Receptor radionuclide therapy is a promising treatment modality for patients with neuroendocrine tumors for whom alternative treatments are limited. The aim of this study was to investigate the incidence of hormonal crises after therapy with the radiolabeled somatostatin analogue [(177...

Descripción completa

Detalles Bibliográficos
Autores principales: de Keizer, Bart, van Aken, Maarten O., Feelders, Richard A., de Herder, Wouter W., Kam, Boen L. R., van Essen, Martijn, Krenning, Eric P., Kwekkeboom, Dik J.
Formato: Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668649/
https://www.ncbi.nlm.nih.gov/pubmed/18210106
http://dx.doi.org/10.1007/s00259-007-0691-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668649/
https://www.ncbi.nlm.nih.gov/pubmed/18210106
http://dx.doi.org/10.1007/s00259-007-0691-z

Ejemplares similares